According to the US Department of Health and Human Services, approximately 42 million Americans suffer from arthritis. The joint care market is continually searching for the next great ingredient. Citrofen is here to fill that void. It is a proprietary blend from the bark of Phellodendron amurense and a patented (US Patent No. 6,184,246) formulation of Polymethoxylated flavones extracted from Citrus sinenis. A connection has been established between osteoarthritis and elevated C-reactive protein, a pro-inflammatory cytokine.
Citrofen was clinically tested on subjects with osteoarthritis of the knee. By bringing CRP into normal range, symptoms of osteoarthritis diminished. Furthermore, weight loss has proven to lessen the pain and severity of OA. The trial conducted on Citrofen showed a statistically significant weight loss in its overweight patients over an 8 week period (p<0.001). Ideal for weight management and increased joint mobility and comfort, Citrofen is the promising new product for the joint care category.